VivoSeq
Neurology

Parkinson's

0

Pipeline Programs↗

3

Active Trials↗

9

Companies Involved↗

Parkinson's is an early-stage landscape with 0 programs across 9 companies. The most active players are AbbVie, Novartis, Allyx Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalA

Allyx Therapeutics

0 programs

PreclinicalA

ApoPharma

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalLundbeck logo

Lundbeck

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed15 · 60%
Recruiting3 · 12%
Terminated3 · 12%
Unknown status2 · 8%
Withdrawn2 · 8%

Clinical Trials

Trial Activity

25 trials

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
Recruiting·AAllyx Therapeutics·Phase 1·NCT06309147·18 enrolled
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
Recruiting·MMichael J. Fox Foundation for Parkinson's Research·Phase 2·NCT07265596·100 enrolled
A Study of NE3107 in Early Parkinson's
Recruiting·BBioVie Inc.·Phase 2·NCT06757010·60 enrolled
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Completed·Novartis logoNovartis·Phase 2·NCT01491932·129 enrolled
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
Completed·BBial - Portela C S.A.·Phase 4·NCT04990284·106 enrolled
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
Completed·AbbVie logoAbbVie·Phase 4·NCT00141518·77 enrolled
Study of Parkinson's Early Stage With Deferiprone
Completed·AApoPharma·Phase 2·NCT02728843·140 enrolled
A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's
Completed·GSK logoGSK·Phase 3·NCT00331149·343 enrolled
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Completed·Novartis logoNovartis·Phase 2·NCT01173731·66 enrolled
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Completed·PPharma Two B Ltd.·Phase 3·NCT03329508·544 enrolled
Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study
Completed·UUniversity Hospital, Toulouse·N/A·NCT00524914·16 enrolled
Idiopathic Parkinson's Progression and Dopamine Transporter SPECT
Completed·—·N/A·NCT03531086·12 enrolled
Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
Completed·Lundbeck logoLundbeck·Phase 3·NCT01479530·321 enrolled
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
Completed·AbbVie logoAbbVie·Phase 3·NCT00360568·62 enrolled
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
Completed·IInstitute for Neurodegenerative Disorders·Phase 2·NCT00129675·169 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)